Back to Clinical Trials

Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

INTRODUCTION

  • Org Study ID: 3475-992
  • Secondary ID: N/A
  • NCT ID: NCT04241185
  • Sponsor: Merck Sharp & Dohme LLC

BRIEF SUMMARY

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

  • Overall Status
    Recruiting
  • Start Date
    May 19, 2020
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Bladder Intact Event-Free Survival (BI-EFS)

Primary Outcome 1 - Timeframe: Up to approximately 71 months

CONDITION

  • Urinary Bladder Neoplasms

ELIGIBILITY

Inclusion Criteria:
* Has a histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology

- * Has clinically nonmetastatic bladder cancer (N0M0)

- * Has planned and is eligible to receive chemoradiotherapy (CRT) and one of the protocol-specified radiosensitizing chemotherapy regimens

- * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- * Demonstrates adequate organ function

- * Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of CRT treatment:
* Refrain from donating sperm

- * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception unless confirmed to be azoospermic

- * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a woman of childbearing potential (WOCBP)

- * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 180 days the time needed to eliminate each study intervention after the last dose of study intervention; and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: MK-3475 - 120 days and CRT - 180 days
Exclusion Criteria:
* Has the presence of diffuse carcinoma in situ (CIS) (multiple foci of CIS) throughout the bladder

- * Has the presence of urothelial carcinoma (UC) at any site outside of the urinary bladder in the previous 2 years except for Ta stage/T1 stage/CIS of the upper tract if the participant has undergone a complete nephroureterectomy

- * Has a known additional malignancy that is progressing or has required active therapy within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or other carcinoma in situ that has undergone potentially curative therapy

- * Has the presence of bilateral hydronephrosis

- * Has limited bladder function with frequency of small amounts of urine (< 30 mL), urinary incontinence, or requires self-catheterization or a permanent indwelling catheter - * Has received prior pelvic/local radiation therapy or any antineoplastic treatment for muscle-invasive bladder cancer (MIBC). Treatment for non-muscle invasive bladder cancer (NMIBC) with intravesical instillation therapy that was completed ≥28 days prior to randomization is allowed. Prior systemic treatment of NMIBC is not permitted. - * Received prior therapy with an anti-PD-1 (programmed cell death protein 1), anti-PD-L1 (programmed death-ligand 1), or anti-PD-L2 (programmed cell death 1 ligand 2), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4 [cytotoxic T-lymphocyte-associated protein 4], OX 40, or CD137 [cluster of differentiation 137]) - * Has received a live vaccine within 30 days before the first dose of study medication - * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study medication - * Has known severe hypersensitivity (≥Grade 3) to the selected chemotherapy regimen, and/or any of their excipients and excipients of pembrolizumab - * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication - * Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed - * Has a history of non-infectious pneumonitis that required steroids or has current pneumonitis - * Has an active infection requiring systemic therapy - * Has a known history of human immunodeficiency virus (HIV) infection - * Has a known history of hepatitis B or known active hepatitis C virus infection - * Has a known history of active tuberculosis (TB; Bacillus tuberculosis) - * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study - * Has had an allogenic tissue/solid organ transplant

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Medical Director

Role: Study Director

Affiliation: Merck Sharp & Dohme LLC

Overall Contact

Name: Medical Director

Phone: 1-888-577-8839

Email: Trialsites@merck.com

LOCATION

Facility Status Contact
Facility: Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041)
Washington, District of Columbia 20010
United States
Status: Recruiting Contact: Contact
Study Coordinator
202-877-9386

Facility: Pikeville Medical Center ( Site 0009)
Pikeville, Kentucky 41501
United States
Status: Recruiting Contact: Contact
Study Coordinator
606-218-2212

Facility: Washington University ( Site 0003)
Saint Louis, Missouri 63110
United States
Status: Recruiting Contact: Contact
Study Coordinator
314-747-4328

Facility: Summit Medical Group Cancer Center ( Site 6008)
Florham Park, New Jersey 07932
United States
Status: Recruiting Contact: Contact
Study Coordinator
855-413-2220

Facility: John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)
Hackensack, New Jersey 07601
United States
Status: Recruiting Contact: Contact
Study Coordinator
551-996-1379

Facility: New York Oncology Hematology P.C ( Site 0024)
Albany, New York 12206
United States
Status: Recruiting Contact: Contact
Study Coordinator
518-489-3612

Facility: Winthrop University Hospital ( Site 0069)
Mineola, New York 11501
United States
Status: Recruiting Contact: Contact
Study Coordinator
516-289-3772

Facility: New York University Perlmutter Cancer Center ( Site 0001)
New York, New York 10016
United States
Status: Recruiting Contact: Contact
Study Coordinator
212-731-6455

Facility: Cleveland Clinic ( Site 0062)
Cleveland, Ohio 44195
United States
Status: Recruiting Contact: Contact
Study Coordinator
866-223-8100

Facility: MidLantic urology ( Site 0070)
Bala-Cynwyd, Pennsylvania 19004
United States
Status: Recruiting Contact: Contact
Study Coordinator
610-667-0458

Facility: Carolina Urologic Research Center ( Site 0002)
Myrtle Beach, South Carolina 29572
United States
Status: Recruiting Contact: Contact
Study Coordinator
843-449-1010 ext. 257

Facility: Urology San Antonio Research ( Site 6010)
San Antonio, Texas 78229
United States
Status: Recruiting Contact: Contact
Study Coordinator
832-472-5482

Facility: Inova Schar Cancer Institute ( Site 6006)
Fairfax, Virginia 22031
United States
Status: Recruiting Contact: Contact
Study Coordinator
571-472-1390

Facility: West Virginia University - Charleston Area Medical Center ( Site 6003)
Charleston, West Virginia 25304
United States
Status: Recruiting Contact: Contact
Study Coordinator
304-388-5432

Facility: Froedtert and Medical College of Wisconsin ( Site 0022)
Milwaukee, Wisconsin 53226
United States
Status: Recruiting Contact: Contact
Study Coordinator
414-805-8900

Facility: Liverpool Hospital ( Site 0220)
Liverpool, New South Wales 2170
Australia
Status: Recruiting Contact: Contact
Study Coordinator
61287389181

Facility: GenesisCare North Shore ( Site 0217)
St Leonards, New South Wales 2065
Australia
Status: Recruiting Contact: Contact
Study Coordinator
61294631172

Facility: Austin Health ( Site 0218)
Heidelberg, Victoria 3084
Australia
Status: Recruiting Contact: Contact
Study Coordinator
610420381848

Facility: Oncocentro Valdivia ( Site 7055)
Valdivia, Los Rios 5112129
Chile
Status: Recruiting Contact: Contact
Study Coordinator
+56992195434

Facility: FALP ( Site 7056)
Santiago, Region M. De Santiago 7500921
Chile
Status: Recruiting Contact: Contact
Study Coordinator
+56956075934

Facility: Bradfordhill-Clinical Area ( Site 7051)
Santiago, Region M. De Santiago 8420383
Chile
Status: Recruiting Contact: Contact
Study Coordinator
+56998744662

Facility: ONCOCENTRO APYS-ACEREY ( Site 7054)
Viña del Mar, Valparaiso 2520598
Chile
Status: Recruiting Contact: Contact
Study Coordinator
+56992369820

Facility: Centro de Investigación Oncológica del Norte ( Site 7052)
Antofagasta, 1240000
Chile
Status: Recruiting Contact: Contact
Study Coordinator
56994198125

Facility: Fakultni nemocnice Olomouc ( Site 0559)
Olomouc, 779 00
Czechia
Status: Recruiting Contact: Contact
Study Coordinator
+420588444295

Facility: 2. LF UK a FN Motol ( Site 0555)
Praha 5, 150 06
Czechia
Status: Recruiting Contact: Contact
Study Coordinator
+420266084516

Facility: North Estonia Medical Centre Foundation ( Site 0081)
Tallin, Harjumaa 13419
Estonia
Status: Recruiting Contact: Contact
Study Coordinator
+3726172323

Facility: Tartu University Hospital ( Site 0079)
Tartu, Tartumaa 51014
Estonia
Status: Recruiting Contact: Contact
Study Coordinator
+3727318815

Facility: Institut Sainte Catherine ( Site 0121)
Avignon, Provence-Alpes-Cote-d Azur 84918
France
Status: Recruiting Contact: Contact
Study Coordinator
+33490276090

Facility: CHU Amiens Picardie Site Sud Amiens ( Site 0123)
Amiens, Somme 80000
France
Status: Recruiting Contact: Contact
Study Coordinator
+3332022087996

Facility: A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 0115)
Paris, 75018
France
Status: Recruiting Contact: Contact
Study Coordinator
+33140258935

Facility: Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0146)
Guatemala, 01010
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+502 42142081

Facility: Oncomedica ( Site 0145)
Guatemala, 01010
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
50222781268

Facility: Grupo Medico Angeles ( Site 0143)
Guatemala, 01015
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50223857572

Facility: Medi-K Cayala ( Site 0142)
Guatemala, 01016
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50223752222

Facility: Centro Medico Integral De Cancerología (CEMIC) ( Site 0144)
Quetzaltenango, 09002
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50259458053

Facility: Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0095)
Kecskemét, Bacs-Kiskun 6000
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3676516719

Facility: BAZ Megyei Korhaz. Klinikai Onkologia es Sugarterapias Centrum ( Site 0092)
Miskolc, Borsod-Abauj-Zemplen 3526
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3646515200

Facility: Petz Aladar Megyei Oktato Korhaz ( Site 0099)
Gyor, Gyor-Moson-Sopron 9024
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3696507900

Facility: Debreceni Egyetem Klinikai Kozpont ( Site 0097)
Debrecen, 4032
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3652255585

Facility: Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0091)
Kaposvar, 7400
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+36306554043

Facility: Soroka Medical Center-Oncology ( Site 7031)
Be'er Sheva, 8400000
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+972508946244

Facility: Rambam Health Care Campus-Oncology Division ( Site 0088)
Haifa, 3109601
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97247773811

Facility: Hadassah Medical Center. Ein Kerem ( Site 0086)
Jerusalem, 9112001
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97226776760

Facility: Chaim Sheba Medical Center ( Site 0087)
Ramat Gan, 5265601
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97235302542

Facility: Sourasky Medical Center ( Site 0089)
Tel Aviv, 6423906
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97236973413

Facility: Fondazione Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 7041)
Roma, Lazio 00128
Italy
Status: Recruiting Contact: Contact
Study Coordinator
3470112401

Facility: Ospedale San Raffaele ( Site 0194)
Milano, Lombardia 20132
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390226435668

Facility: IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0193)
Bari, Puglia 70124
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390805555355

Facility: AOU Careggi ( Site 0191)
Firenze, 50134
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390557947019

Facility: Ospedale Civile di Macerata ( Site 0190)
Macerata, 62100
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+3907332572881

Facility: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0186)
Milano, 20133
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390223903818

Facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0192)
Napoli, 80131
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390815903637

Facility: Hirosaki University Hospital ( Site 0602)
Hirosaki, Aomori 036-8563
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81172335111

Facility: University of Tsukuba Hospital ( Site 0605)
Tsukuba, Ibaraki 305-8576
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81298533900

Facility: Osaka Medical and Pharmaceutical University Hospital ( Site 0604)
Takatsuki, Osaka 5698686
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81726831221

Facility: Nagasaki University Hospital ( Site 0600)
Nagasaki, 852-8501
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81958197200

Facility: Tokyo Medical and Dental University Hospital ( Site 0601)
Tokyo, 113-8519
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81338136111

Facility: Tokyo Metropolitan Komagome Hospital ( Site 0606)
Tokyo, 113-8677
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81-3-3823-2101

Facility: National Cancer Center ( Site 0202)
Gyeonggi-do, Kyonggi-do 10408
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82319203679

Facility: Seoul National University Bundang Hospital ( Site 0204)
Seongnam-si, Kyonggi-do 13620
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82317877071

Facility: Asan Medical Center ( Site 0200)
Songpagu, Seoul 05505
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82230105614

Facility: Chungnam National University Hospital ( Site 0203)
Daejeon, Taejon-Kwangyokshi 35015
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82422808369

Facility: Severance Hospital Yonsei University Health System ( Site 0201)
Seoul, 03722
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82222288138

Facility: Pauls Stradins Clinical University Hospital ( Site 0073)
Riga, 1002
Latvia
Status: Recruiting Contact: Contact
Study Coordinator
+37129262596

Facility: Hospital Universiti Sains Malaysia ( Site 0237)
Kubang Kerian, Kelantan 16150
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+6097676684

Facility: Hospital Pulau Pinang ( Site 0239)
Penang, Pulau Pinang 10990
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+6042225768

Facility: University Malaya Medical Centre ( Site 0236)
Kuala Lumpur, 59100
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+60379492120

Facility: Netherlands Cancer Institute (NKI) ( Site 0183)
Amsterdam, Noord-Holland 1066 CX
Netherlands
Status: Recruiting Contact: Contact
Study Coordinator
+31205122569

Facility: Erasmus MC ( Site 0182)
Rotterdam, Zuid-Holland 3015 GD
Netherlands
Status: Recruiting Contact: Contact
Study Coordinator
+31107041505

Facility: Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0153)
Krakow, Malopolskie 31-826
Poland
Status: Recruiting Contact: Contact
Study Coordinator
48606751459

Facility: Mazowiecki Szpital Wojewódzki w Siedlcach ( Site 0154)
Siedlce, Mazowieckie 08-110
Poland
Status: Recruiting Contact: Contact
Study Coordinator
+48603936331

Facility: Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0152)
Koszalin, Zachodniopomorskie 75-581
Poland
Status: Recruiting Contact: Contact
Study Coordinator
+48943488931

Facility: Centro Hospitalar e Universitario de Coimbra ( Site 0306)
Coimbra, 3000-075
Portugal
Status: Recruiting Contact: Contact
Study Coordinator
+351239400457

Facility: CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0302)
Lisboa, 1449-005
Portugal
Status: Recruiting Contact: Contact
Study Coordinator
+351210431703

Facility: Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria ( Site 0305)
Lisboa, 1649-035
Portugal
Status: Recruiting Contact: Contact
Study Coordinator
+351217805000

Facility: Advance Urology and Laparoscopic Center ( Site 0281)
Ponce, 00716
Puerto Rico
Status: Recruiting Contact: Contact
Study Coordinator
7872843333

Facility: PAN American Center Oncologic ( Site 0280)
San Juan, Rio Piedras, 00935
Puerto Rico
Status: Recruiting Contact: Contact
Study Coordinator
7874073333

Facility: Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249)
Cluj Napoca, Cluj 400015
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40745976913

Facility: S.C. Radiotherapy Center Cluj S.R.L ( Site 0252)
Cluj-Napoca, Cluj 407280
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40742206212

Facility: S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248)
Craiova, Dolj 200542
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40727774974

Facility: Policlinica Oncomed SRL ( Site 0254)
Timisoara, Timis 300239
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40745100495

Facility: S.C.Focus Lab Plus S.R.L ( Site 0253)
Bucuresti, 022548
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40721298677

Facility: Institutul Oncologic-Oncologie Medicala ( Site 0256)
Cluj, 400015
Romania
Status: Recruiting Contact: Contact
Study Coordinator
40745646368

Facility: Instituto Catalan de Oncologia - ICO ( Site 0103)
L Hospitalet De Llobregat, Barcelona 08908
Spain
Status: Recruiting Contact: Contact
Study Coordinator
+34932607744

Facility: Hospital La Fe de Valencia ( Site 0105)
Valencia, Valenciana, Comunitat 46026
Spain
Status: Recruiting Contact: Contact
Study Coordinator
+34961244188

Facility: HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0106)
Sevilla, 41013
Spain
Status: Recruiting Contact: Contact
Study Coordinator
+34955013068

Facility: Chi Mei Medical Center ( Site 0215)
Tainan City, Tainan 71004
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+88662812811

Facility: Kaohsiung Chang Gung Memorial Hospital ( Site 0209)
Kaohsiung, 83301
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
88677317123

Facility: Taichung Veterans General Hospital ( Site 0213)
Taichung, 407
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+8886423592525

Facility: National Taiwan University Hospital ( Site 0210)
Taipei, 10002
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886223123456

Facility: Taipei Veterans General Hospital ( Site 0211)
Taipei, 112
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886228757519304

Facility: Chang Gung Medical Foundation.Linkou Branch ( Site 0212)
Taoyuan, 333
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886 3-3281200 ext8825

Facility: University of Health Sciences,Gulhane School of Medicine-Oncology ( Site 0509)
Ankara, 06010
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
905366401020

Facility: Ankara Universitesi Tip Fakultesi. ( Site 0502)
Ankara, 06100
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905337483275

Facility: Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 0501)
Istanbul, 34098
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905333682319

Facility: T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training (
Istanbul, 34147
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905326761078

Facility: Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0504)
Istanbul, 34722
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905063509061

Facility: Ege University Medical Faculty ( Site 0508)
Izmir, 35100
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905337360674

Facility: Karadeniz Teknik Universitesi Tip Fakultesi ( Site 0503)
Trabzon, 61080
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905052180361

Facility: South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 0444)
Torquay, Devon TQ2 7AA
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+441803614567

Facility: University College London Hospitals NHS Foundation Trust ( Site 0445)
London, London, City Of NW1 2PG
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+4420 3456 7014

Facility: The Royal Marsden NHS Foundation Trust. ( Site 0442)
London, London, City Of SW3 6JJ
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+442078082788

Facility: Nottingham University Hospital NHS Trust ( Site 0250)
Nottingham, Nottinghamshire NG5 1PB
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+441159691169 x71985

Facility: Darlington Memorial Hospital NHS Trust ( Site 0446)
Darlington, DL3 6HX
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+441325743654